Meta Pixel

News and Announcements

Aurora Labs Raises $7m to Fast-Track its 3D Printer Business

  • Published February 24, 2017 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Aurora Labs (ASX: A3D) have successfully raised funds completed from an oversubscribed share placement to raise $7m at $2.50 per share – to fast-track the development of the company’s 3D printers.

KEY TAKEAWAYS:

  • The Perth-based company are developing a range of metal 3D printers that are cheaper than its competitors.
  • The new funds will be spent to accelerate the development + testing of Aurora’s innovative printers.
  • The company listed on the ASX during August 2016 after successfully raising $2.8m through an IPO.

“Aurora burst into investors’ consciousness late last year when the stock, which listed at $0.20, skyrocketed to a peak of $5.35, giving it a market capitalisation of nearly $300 million. The focus of the exuberance is its large-format 3D metal printer prototype that can be used to make metal parts for a variety of industrial applications. Interestingly, Aurora is in discussions with some of the world’s biggest mining companies to reduce their inventories of spare parts through the use of the company’s 3D metal printer. In December 2016, Aurora shipped itsfirst small S-Titanium Pro printer to a buyer. This marked the company’s transition from a developer to a producer of 3D metal printers.”

Aurora Labs has patent-pending technology that has the potential to revolutionize the manufacturing industry. They have developed the world’s first affordable 3D metal printer which is moving to commercialisation in the next few months. They are in the prototyping and testing phase of their ground breaking large format printer which is expected to print 100 times faster than current competing printers with similar resolution.

Capital Insights
The control layer for the electrified home

THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]

Capital Insights
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be  Attracting Big Pharma’s Attention

Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.

Join over 45,000+ sophisticated investors

Join Now